{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:51:01Z","timestamp":1790898661979,"version":"4.1.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012292","name":"Gerstner Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012292","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Homologous recombination deficiency (HRD) is a predictive biomarker for efficacy of PARP (poly ADP-ribose polymerase) inhibition and platinum chemotherapy for cancer patients but remains challenging to detect. The discovery of patients without pathogenic mutations in known HR genes but exhibiting genomic scars indicative of HRD led to the FDA approval of the first scar-based HRD test. Despite advancements in whole genome sequencing (WGS) and integration of large training datasets with machine learning models, current methods lack the sensitivity required for detecting HRD scars in low tumor purity samples, especially in liquid biopsies. Here, we describe DirectHRD, a genomic scar-based HRD classifier based on WGS. Compared to other WGS-based methods, DirectHRD exclusively utilizes a highly specific type of HRD scar\u2014small deletions with microhomology\u2014and its associated signatures in a probabilistic framework. We applied DirectHRD to 501 tumor and 90 cell-free DNA (cfDNA) samples from 4 cancer types: breast, ovarian, prostate, and pancreas. Among all 501 tumor biopsies, DirectHRD achieved 100% detection of HRD with high specificity (&amp;gt;90%). Across all 90 cfDNA samples, the method achieved an area under the curve of 0.87 and demonstrated the ability to detect HRD at tumor fractions as low as 1%, making it 10 times more sensitive than state-of-the-art methods.<\/jats:p>","DOI":"10.1093\/nar\/gkaf313","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T05:32:07Z","timestamp":1744867927000},"source":"Crossref","is-referenced-by-count":8,"title":["DirectHRD enables sensitive scar-based classification of homologous recombination deficiency"],"prefix":"10.1093","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9059-6335","authenticated-orcid":false,"given":"Ruolin","family":"Liu","sequence":"first","affiliation":[{"name":"Broad Institute of MIT and Harvard , Cambridge , MA , 02142,\u00a0","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Roberts","sequence":"additional","affiliation":[{"name":"Broad Institute of MIT and Harvard , Cambridge , MA , 02142,\u00a0","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather\u00a0A","family":"Parsons","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute , Boston , MA ,\u00a002215,\u00a0","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth\u00a0H","family":"Stover","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute , Boston , MA ,\u00a002215,\u00a0","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atish\u00a0D","family":"Choudhury","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute , Boston , MA ,\u00a002215,\u00a0","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Rhoades","sequence":"additional","affiliation":[{"name":"Broad Institute of MIT and Harvard , Cambridge , MA , 02142,\u00a0","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Blewett","sequence":"additional","affiliation":[{"name":"Broad Institute of MIT and Harvard , Cambridge , MA , 02142,\u00a0","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David\u00a0D","family":"Yang","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute , Boston , MA ,\u00a002215,\u00a0","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce\u00a0F","family":"Liu","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute , Boston , MA ,\u00a002215,\u00a0","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica\u00a0L","family":"Mayer","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute , Boston , MA ,\u00a002215,\u00a0","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor\u00a0A","family":"Adalsteinsson","sequence":"additional","affiliation":[{"name":"Broad Institute of MIT and Harvard , Cambridge , MA , 02142,\u00a0","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,22]]},"reference":[{"key":"2025050706450865400_B1","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus Bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N Engl J Med"},{"key":"2025050706450865400_B2","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N Engl J Med"},{"key":"2025050706450865400_B3","doi-asserted-by":"publisher","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","article-title":"Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer","volume":"22","author":"Telli","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2025050706450865400_B4","doi-asserted-by":"publisher","first-page":"3888","DOI":"10.1093\/bioinformatics\/btaa261","article-title":"ShallowHRD: detection of homologous recombination deficiency from shallow whole genome sequencing","volume":"36","author":"Eeckhoutte","year":"2020","journal-title":"Bioinformatics"},{"key":"2025050706450865400_B5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41523-018-0066-6","article-title":"Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer","volume":"4","author":"Sztupinszki","year":"2018","journal-title":"Npj Breast Cancer"},{"key":"2025050706450865400_B6","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.cell.2012.04.024","article-title":"Mutational processes molding the genomes of 21 breast cancers","volume":"149","author":"Nik-Zainal","year":"2012","journal-title":"Cell"},{"key":"2025050706450865400_B7","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1038\/s41588-019-0390-2","article-title":"Detecting the mutational signature of homologous recombination deficiency in clinical samples","volume":"51","author":"Gulhan","year":"2019","journal-title":"Nat Genet"},{"key":"2025050706450865400_B8","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nm.4292","article-title":"HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures","volume":"23","author":"Davies","year":"2017","journal-title":"Nat Med"},{"key":"2025050706450865400_B9","doi-asserted-by":"publisher","first-page":"5584","DOI":"10.1038\/s41467-020-19406-4","article-title":"Pan-cancer landscape of homologous recombination deficiency","volume":"11","author":"Nguyen","year":"2020","journal-title":"Nat Commun"},{"key":"2025050706450865400_B10","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1158\/1078-0432.CCR-19-3005","article-title":"Sensitive detection of minimal residual disease in patients treated for early-stage breast cancer","volume":"26","author":"Parsons","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2025050706450865400_B11","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/s41588-023-01376-0","article-title":"Single duplex DNA sequencing with CODEC detects mutations with high sensitivity","volume":"55","author":"Bae","year":"2023","journal-title":"Nat Genet"},{"key":"2025050706450865400_B12","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41586-020-1969-6","article-title":"Pan-cancer analysis of whole genomes","volume":"578","author":"Aaltonen","year":"2020","journal-title":"Nature"},{"key":"2025050706450865400_B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.2517-6161.1977.tb01600.x","article-title":"Maximum likelihood from incomplete data via the EM algorithm","volume":"39","author":"Dempster","year":"1977","journal-title":"J R Stat Soc Series B Stat Methodol"},{"key":"2025050706450865400_B14","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/j.annonc.2020.08.2064","article-title":"TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker","volume":"31","author":"Mayer","year":"2020","journal-title":"Ann Oncol"},{"key":"2025050706450865400_B15","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.annonc.2023.08.004","article-title":"Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030","volume":"34","author":"Parsons","year":"2023","journal-title":"Ann Oncol"},{"key":"2025050706450865400_B16","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1093\/bioinformatics\/bts271","article-title":"Strelka: accurate somatic small-variant calling from sequenced tumor\u2013normal sample pairs","volume":"28","author":"Saunders","year":"2012","journal-title":"Bioinformatics"},{"key":"2025050706450865400_B17","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41592-018-0051-x","article-title":"Strelka2: fast and accurate calling of germline and somatic variants","volume":"15","author":"Kim","year":"2018","journal-title":"Nat Methods"},{"key":"2025050706450865400_B18","doi-asserted-by":"publisher","article-title":"Calling somatic SNVs and indels with Mutect2","author":"Benjamin","DOI":"10.1101\/861054"},{"key":"2025050706450865400_B19","doi-asserted-by":"publisher","first-page":"100179","DOI":"10.1016\/j.xgen.2022.100179","article-title":"Uncovering novel mutational signatures by de novo extraction with SigProfilerExtractor","volume":"2","author":"Islam","year":"2022","journal-title":"Cell Genomics"},{"key":"2025050706450865400_B20","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/s41467-017-00965-y","article-title":"Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors","volume":"8","author":"Adalsteinsson","year":"2017","journal-title":"Nat Commun"},{"key":"2025050706450865400_B21","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nbt.2514","article-title":"Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples","volume":"31","author":"Cibulskis","year":"2013","journal-title":"Nat Biotechnol"},{"key":"2025050706450865400_B22","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1200\/JCO.2023.41.6_suppl.203","article-title":"Circulating tumor DNA and homologous recombination deficiency in bone-predominant mCRPC prior to radium-223 therapy","volume":"41","author":"Yang","year":"2023","journal-title":"JCO"},{"key":"2025050706450865400_B23","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.3390\/cancers13164055","article-title":"Circulating cell-free DNA as biomarker of taxane resistance in metastatic castration-resistant prostate cancer","volume":"13","author":"Francini","year":"2021","journal-title":"Cancers"},{"key":"2025050706450865400_B24","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1158\/2326-6066.CIR-22-0306","article-title":"Randomized phase II study evaluating the addition of Pembrolizumab to radium-223 in metastatic castration-resistant prostate cancer","volume":"12","author":"Choudhury","year":"2024","journal-title":"Cancer Immunol Res"},{"key":"2025050706450865400_B25","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/nbt.4235","article-title":"A universal SNP and small-indel variant caller using deep neural networks","volume":"36","author":"Poplin","year":"2018","journal-title":"Nat Biotechnol"},{"key":"2025050706450865400_B26","doi-asserted-by":"publisher","first-page":"11.10.1","DOI":"10.1002\/0471250953.bi1110s43","article-title":"From FastQ data to high-confidence variant calls: the genome analysis toolkit best practices pipeline","volume":"43","author":"Van","year":"2013","journal-title":"Curr Protoc Bioinformatics"},{"key":"2025050706450865400_B27","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41551-022-00855-9","article-title":"Massively parallel enrichment of low-frequency alleles enables duplex sequencing at low depth","volume":"6","author":"Gydush","year":"2022","journal-title":"Nat. Biomed. Eng"},{"key":"2025050706450865400_B28","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1200\/PO.19.00345","article-title":"Pan-cancer analysis of BRCA1 and BRCA2 genomic alterations and their association with genomic instability as measured by genome-wide loss of heterozygosity","volume":"4","author":"Sokol","year":"2020","journal-title":"JCO Prec Oncol"},{"key":"2025050706450865400_B29","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1172\/jci.insight.152789","article-title":"Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancer","volume":"6","author":"De","year":"2021","journal-title":"JCI Insight"},{"key":"2025050706450865400_B30","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1093\/annonc\/mdy216","article-title":"Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors","volume":"29","author":"Diossy","year":"2018","journal-title":"Ann Oncol"},{"key":"2025050706450865400_B31","doi-asserted-by":"publisher","first-page":"e2200258","DOI":"10.1200\/PO.22.00258","article-title":"Homologous recombination repair gene mutations to predict olaparib plus bevacizumab efficacy in the first-line ovarian cancer PAOLA-1\/ENGOT-ov25 trial","volume":"7","author":"Pujade-Lauraine","year":"2023","journal-title":"JCO Precis Oncol"}],"container-title":["Nucleic Acids Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/nar\/article-pdf\/53\/8\/gkaf313\/63080879\/gkaf313.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/nar\/article-pdf\/53\/8\/gkaf313\/63080879\/gkaf313.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T06:45:13Z","timestamp":1746600313000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/nar\/article\/doi\/10.1093\/nar\/gkaf313\/8117946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,22]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,4,22]]}},"URL":"https:\/\/doi.org\/10.1093\/nar\/gkaf313","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.06.21.600073","asserted-by":"object"}]},"ISSN":["0305-1048","1362-4962"],"issn-type":[{"value":"0305-1048","type":"print"},{"value":"1362-4962","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5,8]]},"published":{"date-parts":[[2025,4,22]]},"article-number":"gkaf313"}}